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1. Introduction  
Despite numerous studies focusing on the aortic aneurysm pathogenesis, the mechanism of 
aneurysm formation, especially – initiation of this process, remains unclear. The research 
concerning both, structural and molecular studies, is based on two main data sources. The 
first source of information are patients with already formed aneurysm, and with well 
defined biochemical and morphological changes in aortic wall architecture. The other source 
of data are experimental studies based on laboratory animals with artificially induced 
aneurysms. This approach enables verification of various hypotheses concerning 
pathogenesis of aortic aneurysm. Regrettably, animal aneurysm models, although similar, 
are not exactly the same, as human pathology. Thus, since the link between both mentioned 
data sources is still lacking, the knowledge achieved to date, even being highly profound, is 
not sufficient to fully understand this disease. Besides well defined factors, predisposing to 
formation of aortic aneurysm (patient’s age, cigarette smoking, arterial hypertension, 
atherosclerosis, as well as the Marfan’s and the Ehlers-Danlos’s syndrome-associated 
mutations), increasing popularity is currently being gained by the hypothesis concerning the 
pivotal role of proteolytic enzymes - matrix metalloproteinases (MMPs) in aortic wall 
destruction. The involvement of MMPs in extracellular matrix damage in aortic aneurysm is 
doubtless. However, it needs to be elucidated, what the sequence of events is and what the 
exact role of MMPs is in these events. MMPs could play a role of “executioners”, that are 
produced and activated in the aortic wall as constituents of inflammatory reaction, in 
response to some yet poorly defined triggers. On the other hand, it is plausible, that aortic 
wall destruction, followed by inflammatory response to tissue degradation products, results 
from primary local overproduction and/or activation of proteases. It could be due to some 
mutations or polymorphisms of MMP genes, or some impairment in their controlling 
mechanisms. In that circumstance MMPs could rather be considered as “executors”, with 
causative role in aortic aneurysm pathogenesis. Although the majority of studies suggest the 
first scenario as being more possible, there is some evidence, that could support the second 
alternative, too. 
2. Chronic inflammation – where the chaos begins… 
The histopathological assessment of aneurismal aortic wall specimens reveals widespread 
chronic inflammatory reaction. This reaction is associated with extensive destruction of 
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elastic fibers in the tunica media layer, and infiltration of both, media and adventitia, by 
macrophages and lymphocytes, mainly the Th2 subset. Moreover, as has been found 
recently, outer media and adventitia of human aortic aneurysm samples contain 
numerous mast cells (Miyake & Morishita, 2009; Michel et al., 2011). In addition to the 
previously mentioned lymphocytes and macrophages, mast cells are currently recognized 
as a third considerable source of pro-inflammatory cytokines, including tumor necrosis 
factor (TNF), various chemokines, and interleukins. Furthermore, in cooperation with 
macrophages, mast cells produce and release large quantities of various proteases and, 
thus, they are also actively engaged in aortic wall destruction (Tsuruda et al., 2008). 
However, a trigger of inflammatory reaction still remains to be a missing component of 
this scenario. 
2.1 Chronic proteolytic atherothrombosis – a new concept 
Recently, it has been proposed, that the aneurysm pathogenesis could be explained, at least 
to some extent, by the model of chronic proteolytic atherothrombosis (Michel et al., 2011). 
This model is based on the observation that the development of aortic aneurysms is 
accompanied by the formation of chronic intraluminal thrombus inside the aneurysmal sac. 
It has been shown that the presence of intraluminal thrombus is associated with widespread 
degradation of elastic fibers, increased apoptosis and loss of vascular smooth muscle cells 
(VSMC) in tunica media, and with extensive inflammatory reaction in adventitia. It may 
suggest, that the thrombus rather, than the aortic wall, could be the primary source of 
various pro-inflammatory factors, including proteolytic enzymes (Michel et al., 2011). On 
the other hand, one can argue that formation of thrombus on the inner, luminal surface of 
the aortic wall could be secondary to already existing aortic wall inflammation, due to the 
damage of endothelium and tunica intima. Nevertheless, it is plausible, that independently 
of the sequence of events, the thrombus-aortic wall  interface may be “the place, where the 
chaos begins”… 
The pathophysiological role of intraluminal thrombus may be described by various 
activities of its components. The first activity could be a generation of free radicals and 
induction of oxidative stress reaction, mainly due to a degradation of red blood cells and 
release of the potent pro-oxidant mediator – iron-rich hemoglobin. The oxidative stress leads 
to the production of reactive oxygen and reactive nitrogen species, which are both 
components of a self-augmenting mechanism (Miyake & Morishita, 2009). Reactive oxygen 
and nitric oxide increase expression of pro-inflammatory cytokines, followed by further up-
regulation of reactive oxygen species production, peroxidation of membrane phospholipids 
and generation of eicosanoids and pro-apoptotic ceramides. Finally, reactive oxygen species 
induce activation of nuclear factor kappa-B (NF-κB), that leads to additional increase in 
MMPs expression and initiates the apoptosis of VSMC in the aortic wall. In addition to 
erythrocytes, intraluminal thrombus consists of an approximately 12-fold higher number of 
neutrophils, as compared to circulating blood (Michel et al., 2011). These cells produce a 
large number of proteinases, including elastase, cathepsin, MMP-8 and -9. Moreover, strong 
proteolytic activity between the thrombus and the adjacent aneurysm wall is revealed by the 
plasmin. This activity, although originally aimed at the thrombus fibrin network, may also 
contribute to aortic wall destruction. It may occur mainly through degradation of 
fibronectin, thus resulting in mesenchymal cells detachment and apoptosis, as well as direct 
activation of pro-MMPs. 
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2.2 Chlamydia pneumoniae and MMPs in aortic aneurysm 
According to “infection hypothesis”, the chronic inflammatory reaction, which takes place 
in the aortic wall, may be initiated by some pathogens. However, studies focusing on the 
presumed importance of various Chlamydia species, Helicobacter pylori, Borrelia burgdorferi, 
Cytomegalovirus, Herpes simplex virus, and most recently, some comensal, or weak pathogenic 
bacteria from the oral cavity, including Porphyromonas gingivalis and Streptococcus mutans, 
have failed to reveal a direct relationship between the presence of pathogen and aneurysm 
formation. Nevertheless, there is still no consensus in the debate concerning the significance 
of intracellular bacteria Chlamydia (Chlamydophila) pneumoniae in that event. It has been 
shown that almost half of aortic aneurysm specimens contained this pathogen. Moreover, a 
high prevalence of C. pneumoniae seropositivity and the presence of C. pneumoniae-reactive T 
lymphocytes in aortic aneurysm-suffering individuals, seemed to further support this 
hypothesis. Strong evidence was also provided by the results of experimental studies 
indicating, that in animal models C. pneumoniae antigens stimulated an elastin degradation 
followed by dilatation of aorta (Petersen et al., 2002). It is plausible that C. pneumoniae 
infection may reveal such destructive influence on the aortic wall due to activation of 
inflammatory reaction, mainly by stimulation of tissue macrophages with C. pneumoniae 
heat shock protein 60. This stimulation could lead to the release of a variety of pro-
inflammatory molecules, eicosanoids, cytokines and several MMPs. Thus, although the 
exact role of C. pneumoniae in pathogenesis of aortic aneurysm remains to be clarified, the 
results of several prospective clinical trials could provide some contribution to this matter. It 
has been proven, that antibiotics effective against C. pneumoniae – tetracyclines (doxycyclin) 
and macrolides (roxithromycin, but not azithromycin), may reduce the progression of small 
aortic aneurysm (Høgh et al., 2009, see also chapter 3.5.2.2). Based on mentioned 
observations one can expect a direct correlation between the presence of C. pneumoniae and 
tissue levels of MMPs in aneurismal aortic wall specimens. This hypothesis was tested by 
Petersen and coauthors (Petersen et al., 2002). Surprisingly, the authors found, that mean 
levels of MMP-2 and MMP-9 in C. pneumoniae-positive aortic wall specimens were lower, 
than in C. pneumoniae-negative samples. This astonishing result was explained by the 
authors as a consequence of possible irregular distribution of bacteria in the aortic wall. 
Since the C. pneumoniae detection and determination of MMPs activity were done using 
specimens from different locations, some of them could possibly display false negative 
results. It is noteworthy, that problems with detection of C. pneumoniae DNA in tissue 
specimens of Chlamydia-seropositive patients with abdominal aortic aneurysms have also 
been reported by other authors (Falkensammer et al., 2007). An additional cause behind 
such results in Petersen’s study could be the relatively small patient groups (28 individuals, 
divided into 4 groups, 7 patients in each). Moreover, the results of gelatin zymography 
could be affected by components of the extraction buffer used for analysis of MMP activity, 
especially EDTA and potent proteinase inhibitor – phenyl methylsulphonylfluoride (PMSF). 
Finally, authors suggested that C. pneumoniae infection may result in activation of some 
other, different from MMP-2 or MMP-9, proteolytic enzymes, e.g. neutrophil- or mast cells-
derived proteinases, like cathepsins G, or chymase. These enzymes can also reveal elastolytic 
activity, and therefore may directly contribute to the aortic wall destruction (Miyake & 
Morishita, 2009; Michel et al., 2011). Furthermore, it has been demonstrated, that mast cell-
derived chymase could activate pro-enzyme forms of MMP-2 and -9 in aneurysm tissue. 
However, although these observations could confirm the association of C. pneumoniae with 
MMPs activation in pathogenesis of aortic aneurysm, this issue still requires further studies. 
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3. Matrix metalloproteinases – the dark side of the Force… 
Matrix metalloproteinases (MMPs), also known as matrix metallopeptidases, or matrixins, 
belong to the large and still expanding family of zinc endoproteinases. The members of this 
evolutionarily ancient group were found in various organisms, from bacteria and plants, 
through hydra and worms, to humans. So far, at least 25 distinct MMPs have been identified 
in vertebrates. In humans a presence of 23 proteins, encoded for 24 distinct genes, has been 
confirmed. This discrepancy is due to the fact that human MMP-23 was found to be encoded 
by two identical genes located on chromosome 1. Together with the astacins, the 
adamalysins, and large bacterial proteinases – serralysins, MMPs constitute a huge 
superfamily of enzymes, called metzincins, which are characterized by the presence of the 
zinc-binding motif, with a conserved methionine nearby. 
MMPs play a crucial role in extracellular matrix (ECM) turnover. They are able to cleave 
main ECM components, including collagens, elastin, fibronectin, gelatin and aggrecan, as 
well as a variety of non-ECM molecules – transforming growth factor (TGF)-ǃ, pro-IL-1ǃ, 
pro-IL-8, Fas ligand, and pro-TNF. Moreover, MMPs are responsible for the release of 
cryptic fragments and neo-epitopes from extracellular matrix and non-ECM 
macromolecules, which may reveal bioactivities different from those of the parent 
molecules. Furthermore, MMPs may liberate numerous growth factors (e.g. vascular 
endothelial growth factor – VEGF and TGF-ǃ) and cytokines, which are embedded in 
extracellular matrix and require proteolytic release from binding proteins for their 
activation. Finally, MMPs may modify cells’ attachment to the ECM by processing of 
syndecans, dystroglycan and other adhesion molecules (Endo et al., 2003; Yamada et al., 
2001; Mott & Werb, 2004). These properties of MMPs make them key players in the majority 
of physiological conditions (e.g. pregnancy, embryogenesis, wound healing), but also in 
various pathologies, including cancer progression with metastases, liver fibrosis, 
periodontal disease, multiple sclerosis and vascular diseases, especially atherosclerosis and 
aortic aneurysm (Hadler-Olsen et al., 2011). 
As mentioned previously, MMPs should not only be recognized as typical 
effector/”executioner” molecules, but also, at least in some circumstances, they may be 
considered as real causative factors/”executors”. This status may be supported by results of 
studies concerning the genetic polymorphisms of MMP genes. The polymorphisms are 
natural differences in DNA sequence that occur in more than 1% of the entire population. 
The vast majority of them concern variability of single nucleotides and are known as single 
nucleotide polymorphisms (SNPs). The effect of particular SNP is determined by its position 
in a gene structure. Most SNPs are functionally neutral. However, some of them may lead to 
an amino acid substitution, thus influencing the structure and properties of encoded 
protein. Furthermore, some SNPs located in a promoter region may alter the level of gene 
transcription. There is the reason, for which functional SNPs may contribute to the 
individual susceptibility to common diseases, including aortic aneurysms. In this chapter 
authors will shortly review several polymorphisms of selected MMP genes, which have 
been suspected of being involved in aortic aneurysm development. 
3.1 MMPs structure 
The overall scheme of a protein structure is common among all MMPs, with more or less 
significant differences between particular groups (Fig. 1). 
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Fig. 1. The schematic structure of MMPs family 
In general, on its N-terminus the MMP molecule contains a signal sequence, which directs 
the protein to the secretory pathway, and is removed during insertion of the protein into an 
endoplasmic reticulum. The signal sequence is followed by the propeptide composed of 
approximately 80 amino acid residues, that contains a characteristic conserved PRCGXPD 
motif, known as “cysteine-switch”. The role of this sequence is to block a catalytic zinc and 
thus maintain the latent form of an enzyme. The next, the catalytic domain, has a sphere-like 
shape with an active site containing two atoms of zinc inside a large, shallow cleft. The 
catalytic domain is composed of approximately 160-170 amino acids, with a unique 
HEXXHXXGXXH sequence, that binds zinc ions. The last, approximately 200 amino acid 
residues-long C-terminal domain, called the hemopexin-like domain is found in all MMPs 
except for MMP-7, -23 and -26. In most MMPs the hemopexin-like domain is linked to a 
catalytic domain through a short, approximately 10-30 amino acid residues-containing hinge 
region. Exceptionally, the hinge region of MMP-9 is 64 amino acids-long, and is strongly O-
glycosylated. Furthermore, six representatives of the membrane type (MT) MMPs subgroup 
hold either a type I transmembrane domain with a short intracellular segment (MT1, -2, -3 
and -5-MMP) or a cell membrane-anchoring glycosylphosphatidylinositol (GPI) moiety 
(MT4- and -6-MMP). 
Unlike other MMPs, in the MMP-23 molecule, a cystein-rich segment with an 
immunoglobulin-like domain is present, instead of the hemopexin-like domain on C-
terminus, whereas the N-terminal signal peptide has been replaced by an N-terminal type II 
transmembrane domain. In addition to the previously mentioned common components, 
other elements, attached to the catalytic domain are fibronectin II-like inserts, which are 
found in MMP-2 and -9 molecules exclusively. Furthermore, three of the secreted MMPs 
(MMP-11, -21 and -28), as well as all the membrane-anchored MMPs, have a unique 
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sequence R(X/R)KR between the prodomain and the catalytic domain. This motif is 
recognized and cleaved by a serine proteinase – furin, that results in removal of prodomain 
from the active site of the catalytic domain, followed by intracellular activation of 
mentioned MMPs (Fanjul-Fernandez et al., 2010).  
3.2 Classification of MMPs 
Traditionally, MMPs were classified into 6 main groups – collagenases, gellatinases, 
stromelysins, matrilysins, membrane type MMPs and others, unclassified to former groups. 
However, increasing knowledge, concerning the molecular structure, substrate specificity 
and mechanism of MMPs activation contributed to an arrangement of their new 
classification. According to this classification, MMPs are divided into four groups: 
archetypal MMPs, matrilysins, gelatinases and furin-activated MMPs (Fanjul-Fernandez et 
al., 2010, Hadler-Olsen et al., 2011) 
3.2.1 Archetypal MMPs 
Archetypal MMPs have the structure typical for all MMPs. They are further divided into 
three subgroups: collagenases, stromelysins and other archetypal MMPs. 
3.2.1.1 Collagenases 
This subgroup of archetypal MMPs is represented by three enzymes: collagenase-1 (MMP-
1), collagenase-2 (MMP-8), and collagenase-3 (MMP-13). Their main common feature is the 
ability to cleave native collagens into characteristic N-terminal ¾ and C-terminal ¼ 
fragments (Fanjul-Fernandez et al., 2010). Since the triple helix conformation of native 
collagens is highly resistant to cleavage mediated by other proteinases, collagenases are 
crucial enzymes for initiation of collagen degradation. After the cleavage mediated by 
collagenases, the native collagens rapidly denature to gelatin and thus they become 
susceptible to degradation by other MMPs. 
Besides the native fibrillar collagens (types I, II, III, V, and XI), the other targets for 
collagenases are numerous extracellular matrix components, as well as non-ECM molecules, 
including IL-8, pro-TNF, protease-activated receptor-1, several insulin-like growth factor-
binding proteins (IGFBPs), etc… (Gearing et al., 1994; Boire et al., 2005; Amalinei et al., 
2007). 
The activation of MMP-1 requires a presence of active MMP-3 or plasminogen 
activator/plasmin system. The main sources of collagenases are stimulated fibroblasts 
(MMP-1), neutrophils (MMP-8) and VSMC (MMP-1 and MMP-13). Increased levels of 
mRNA and proteins for collagenases were found in aortic aneurysm tissue (Kadoglou & 
Liapis, 2004). Moreover, they are supposed to be involved in aneurysm rupture. 
The studies focused on a presumable connection between aortic aneurysm formation and 
known SNPs in genes encoding for collagenases, including potentially clinically relevant 
SNP in MMP-1 promoter region (-1607 G/GG), did not reveal any significant correlation 
(Ogata et al., 2004; Sandford et al., 2007; Saratzis et al., 2011). 
3.2.1.2 Stromelysins 
The members of this group are stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10). Both 
stromelysins have a structure analogous to that of collagenases, however, in contrast to 
those enzymes, stromelysins are not able to cleave native collagen. Their substrates 
include processed collagen types III, IV, V, IX and X, laminin, gelatin, fibronectin, 
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proteoglycans and several other molecules, e.g. plasminogen, fibrinogen and IL-1ǃ 
(Amalinei et al., 2007). Although both stromelysins display similar substrate specificity, 
MMP-3 reveals a grater proteolytic activity, as compared to MMP-10. Furthermore, MMP-
3 is known to activate various pro-MMPs (collagenases and gelatinases) by removal of 
their pro-domain, and therefore it is crucial for their activation (Suzuki et al., 1990; Visse 
& Nagase, 2003). Stromelysins may be produced by fibroblasts and epithelial cells, 
however, in aortic aneurysm tissue their main source seem to be macrophages (Fanjul-
Fernandez et al., 2010). 
The possible clinical relevance of nucleotide polymorphism in promoter region of genes 
encoding for both, MMP-3 and MMP-10, has been studied by several authors (Sandford et 
al., 2007; Saratzis et al., 2011). It has been found, that in the MMP-3 promoter, at the position 
-1171, corresponding to the transcriptional start site, two variants – one of them, containing 
5 adenosines (5A) and the other one with 6 adenosines (6A), may be present. In vitro tests 
have shown, that the 5A allele has nearly two fold higher activity, than the 6A variant. 
Presumably, this could be due to the higher affinity of the transcriptional repressor p50/p50 
to 6A, than to the 5A allele. Epidemiological studies have shown, that the mentioned 5A/6A 
polymorphism of MMP-3 promoter may be associated with various cardiovascular diseases. 
It was revealed that 5A/5A homozygotic individuals are significantly more susceptible to 
hypertension, myocardial infarction and coronary artery aneurysms. 
Interestingly, the 6A/6A variant carriers displayed a higher growth rate of atherosclerotic 
plaque, which, on the other hand, was more stable, than in patients with the 5A allele. Yoon 
and coauthors have observed a trend (p=0.06) for a higher 5A allele frequency in a small 
cohort of 47 Finnish patients with abdominal aortic aneurysm (Yoon et al., 1999). The higher 
5A allele frequency among aortic aneurysm-suffering patients compared to a control group 
was also confirmed in a British population (Ye, 2006). 
In contrast to MMP-3, studies concerning the presumable role of MMP-10 gene 
polymorphisms, including -180 A/G SNP, have failed to reveal any significant correlation 
with a prevalence of aortic aneurysm (Ogata et al., 2005). 
3.2.1.3 Other archetypal MMPs 
This subgroup of archetypal MMPs includes four enzymes: MMP-12, MMP-19, MMP-20 and 
MMP-27. The representative of this subgroup – MMP-12, also known as macrophage 
metalloelastase, is mainly expressed and secreted by activated macrophages and is 
necessary for its migration (Visse & Nagase, 2003; Kadoglou & Liapis, 2004). The main 
substrate for MMP-12 is elastin, but the enzyme may cleave some other ECM molecules, 
including aggrecan, fibronectin, laminin, and type IV collagen. 
The increased expression of MMP-12 was found exclusively in aortic aneurysm wall, but not 
in the control, or atherosclerotic aorta specimens. Immunohistochemical studies have 
localized MMP-12 within the media of aortic aneurysms, predominantly in zones adjacent to 
non-dilated aorta. However, although MMP-12 is recognized as a key player in aneurysm 
formation, its prominent role has been neglected in the elastase-induced aneurysm animal 
model. Interestingly, it has been found that MMP-12-deficient mice revealed aortic 
dilatation similar to that of wild type animals, whereas mice lacking MMP-9 were resistant 
to aneurysm induction. Therefore, it was suggested that MMP-12 role is restricted rather to 
supporting other MMPs in aneurysm formation (Kadoglou & Liapis, 2004). 
The analysis of polymorphic sites in the MMP-12 gene and in vitro studies suggested the 
possible connection between A to G substitution in -82 position of the promoter and the 
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aortic aneurysm expansion. However, none of the clinical trials have confirmed the expected 
correlation to date (Sandford et al., 2007; Saratzis et al., 2011). 
 
Group Subgroup MMP Common name 
Substrates 
ECM Non-ECM 
Archetypal 
MMPs 
Collagenases
MMP-1 Collagenase-1
Collagens (I, II, III, VII, 
VIII and X), gelatin, 
proteoglycan link protein, 
aggrecan, veriscan, 
tenacin, entactin 
ǂ1-PI, ILb-1, pro-
TNF, IGFBP-3, MMP-
2, MMP-9 
MMP-8 Collagenase-2
Collagens (I, II, III, V, VII, 
VIII and X), gelatin, 
aggrecan 
ǂ1-PI, ǂ2-
antiplasmin, 
fibronectin 
MMP-13 Collagenase-3
Collagens (I, II, III, IV, IX, 
X, XIV), gelatin, aggrecan, 
perlecan, large tenascin-C, 
fibronectin, osteonectin 
MMP-9, plasminogen 
activator inhibitor-2 
Stromelysins
MMP-3 Stromelysin-1 
Collagens (III, IV, V and 
IX), gelatin, aggrecan 
versican, hyaluronidase-
treated versican, perle- 
can, decorin, proteoglycan 
link protein, large 
tenascin-C, fibronectin, 
laminin, entactin, 
osteonectin 
ǂ1-PI, antithrombin-
III, ovosstatin, 
substance P, IL-1ǃ, 
serum amyloid A, 
IGFBP-3, fibrinogen 
and cross- linked 
fibrin, plasminogen,  
MMP-2/TIMP-2 
complex MMP-1,-7,-
8,-9,-13 
MMP-10 Stromelysin-2 
Collagens (III, IV and V), 
gelatin, casein, aggrecan, 
elastin, proteoglycan link 
protein 
MMP-1,-8 
Other 
Archetypal 
MMP-12 Metalloelastase 
Collagen IV, gelatin, 
elastin, casein, laminin, 
proteoglycan monomer, 
fibronectin, vitronectin, 
enactin 
ǂ1-PI, fibrinogen, 
fibrin, fibrin, 
plasminogen, myelin 
basic protein 
MMP-19 RASI Gelatin ND 
MMP-20 Enamelysin Amelogenin ND 
MMP-27              -                                                     ND 
Matrilysins 
MMP-7 Matrilysin 
Collagens IV and X, 
gelatin, aggrecan, decorin, 
proteoglycan link protein, 
fibronectin, laminin, 
insoluble fibronectin 
fibrils, entactin, large and 
small tenascin-C, 
osteonectin, ǃ4 integrin, 
elastin, casein, transferrin
MMP-1,-2,-9 ǂ1-PI,  
MMP-9/TIMP-1 
complex, 
plasminogen 
MMP-26 Matrilysin-2 
Collagen IV, gelatin, 
fibronectin 
ProMMP-9, 
fibrinogen, ǂ1-PI 
ND-not determined 
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3.2.2 Matrilysins  
Matrilysins are represented by matrilysin-1 (MMP-7) and matrilysin-2 (MMP-26, or 
endometase). The most prominent feature of matrilysins group members is the lack of the 
hemopexin domain. MMP-26 is the smallest known MMP; it is composed of only 261 amino 
acids and may activate itself by autocatalysis. Matrilysins play an important role in 
degradation of ECM molecules, including type IV collagen, laminin, entactin, as well as 
several cell surface molecules, e.g. Fas ligand, E-cadherin and syndecan-1 (Fanjul-Fernandez 
et al., 2010). Due to a shedding of membrane-bound Fas ligand and generation of its soluble 
form, matrilysins may stimulate apoptosis. Furthermore, while cleaving plasminogen to 
produce an angiostatin fragments, matrilysins are involved in inhibition of angiogenesis. 
Interestingly, MMP-26 has an ability to activate pro-MMP-9 in a specific site, that results in 
better stability of MMP-9 (Zhaoet al., 2003; Amalinei et al., 2007). Moreover, intracellular 
MMP-26 was found to process the estrogen receptor ǃ, therefore in patients with breast 
cancer an increased MMP-26 level was found to correlate with longer survival (Hadler-
Olsen et al., 2011 ) 
3.2.3 Gelatinases 
The group of gelatinases consists of two members: gelatinase A (MMP-2) and gelatinase B 
(MMP-9). Both of them are constitutively expressed by many cells, including fibroblasts, 
keratinocytes, endothelial cells, polymorphonuclear leukocytes, monocytes, alveolar 
macrophages and osteoclasts. When compared to other MMPs, the most significant 
difference in the structure of gelatinases is the presence of three type II fibronectin-like 
repeats within the catalytic domain. They are responsible for recognition and binding of 
denatured collagen and gelatin molecules (Visse & Nagase, 2003). Gelatinases may cleave 
various extracellular matrix molecules, e.g. collagen types I, IV, V, VII, IX, X, elastin, 
fibronectin, aggrecan, vitronectin, laminin, as well as numerous non-ECM molecules, 
including pro-TNF, TGF-ǃ, pro-IL-1ǃ and pro-IL-8 (Fanjul-Fernandez et al., 2010). Moreover, 
they are involved in generation of several pro- and anti-angiogenic factors, which may 
originate from both, ECM and non-ECM substrates (Mott & Werb, 2004). 
Gelatinases are considered the most important members of the MMPs family, involved in 
pathogenesis of aortic aneurysm. The amounts of mRNA and specific proteins in the 
aneurysm wall, as well, as plasma levels of both, MMP-2 and MMP-9, were statistically 
significantly higher in patients with aortic aneurysms, as compared to healthy controls. 
Moreover, it has been found that plasma levels of gelatinases noticeably correlate with 
aneurysm expansion rate and therefore they were suggested as presumable predictors of the 
aneurysm rupture risk. In an animal experimental study it was proven, that infusion of 
gelatinases resulted in development of aortic aneurysms. Interestingly, MMP-2- and/or 
MMP-9-deficient mice were resistant to aneurysm formation in this model (Longo et al., 
2002; Baxter, 2004; Kadoglou & Liapis, 2004). 
Recently, it has been postulated, that, in addition to elastin degradation, gelatinases may 
also be engaged in the pathogenesis of aortic aneurysm in a proteolysis-independent 
fashion. This hypothesis is based on the observation, that both, MMP-2 and MMP-9, may 
display some inhibitory influence on the calcium-dependent contraction of VSMC isolated 
from the aortic wall (Raffetto & Khalil, 2008). In addition to maintenance of aortic wall 
integrity, the contraction of those cells is considered as a counterbalance of hemodynamic 
forces, that protects the aorta against dilatation during each cardiac cycle. Thus, the MMP-
www.intechopen.com
 Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
34
mediated reversible inhibition of vascular myocytes contraction could promote aneurysm 
progression. However, this issue requires further elucidation. 
3.2.3.1 MMP-2 (Gelatinase A) 
MMP-2, or gellatinase A, is constitutively expressed by vascular myocytes, however, it may 
be produced in small amounts by macrophages and fibroblasts, too. As described in  chapter 
3.4, the activation of MMP-2 occurs mainly by its interaction with MT1-MMP/TIMP-2. Due 
to its elastolytic activity, MMP-2 is believed to play a pivotal role in aortic aneurysm 
development. It was found, that VSMC isolated from aortic aneurysm tissue produced 
higher amounts of MMP-2, as compared to those from atherosclerotic, or normal aortic wall. 
Surprisingly, the activity of MMP-2 negatively correlated with aneurysms diameter. This 
observation could support the opinion, that MMP-2 may be essential in the early stages of 
aneurysm development. Besides weakness of the aortic wall, MMP-2-mediated degradation 
of elastic fibers may lead to production of elastin-derived peptides, which have a great 
chemotactic potential. These peptides may promote recruitment of inflammatory cells and 
enhance further proteolysis. Moreover, MMP-2 liberates TGF-ǃ from an inactive 
extracellular complex consisting of TGF-ǃ, latent TGF-ǃ binding protein and TGF-ǃ-latency 
associated protein, which may stimulate various MMPs expression and results in further 
progression of the disease (Rizas et al., 2009). 
Among 18 polymorphisms found in the MMP-2 gene, the SNP located in a promoter (-1306 
C/T) was initially considered as clinically relevant. The studies focusing on the influence of 
this particular SNP on promoter function have shown, that the presence of C allele was 
associated with a higher promoter activity (Price et al., 2001). However, none of clinical 
studies, addressed at verifying a possible correlation between -1306 C/T SNP and aortic 
aneurysm prevalence, has revealed such a connection (Eriksson et al., 2005; Ogata et al., 
2005; Sandford et al., 2007; Saratzis et al., 2011). 
3.2.3.2 MMP-9 (Gelatinase B) 
MMP-9, or gellatinase B, is mainly produced by macrophages and neutrophils. 
Subsequently to proteolytic activation by a variety of factors, including plasminogen 
activators and other MMPs (MMP-2, -3, -12), MMP-9 displays elastolytic, collagenolytic and 
gelatinolytic activity. The leader position of MMP-9 in the pathogenesis of aortic aneurysm 
may be confirmed by several observations. Animal studies have shown, that MMP-9-
deficient mice were resistant to experimentally induced aortic dilation and they did not 
reveal elastin degradation despite the presence of inflammatory cell in the aortic wall 
(Kadoglou & Liapis, 2004; Baxter, 2004). On the other hand, among all metalloproteinases, 
MMP-9 is the most abundantly expressed enzyme in aortic aneurysm wall, in contrast to 
normal aortic tissue, where it was not present. Also, huge amounts of MMP-9 are released 
by neutrophils trapped in the intraluminal thrombus (see also chapter 2.1). Furthermore, 
high MMP-9 concentrations were detected in ruptured aneurysms. However, although 
patients with an aortic aneurysm have significantly higher levels of MMP-9, than control 
individuals, there is no consensus regarding a direct correlation between MMP-9 plasma 
levels and aneurysm progression and rupture risk to date (Takagi et al., 2009; Eugster et al., 
2005). Therefore, this issue still requires further elucidation. 
Several polymorphisms have been found in the MMP-9 gene. Most of the studies have 
focused on -1562 C/T polymorphism in a promoter region. It has been proven that a 
common T to C substitution in -1562 position of the MMP-9 promoter is associated with 
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approximately 50% increase of the promoter activity. A clinical study by Medley and 
coauthors has shown that mRNA level, protein concentration, as well as enzymatic activity 
of MMP-9 in aortic aneurysm tissues of -1562 T allele carriers were significantly higher, as 
compared to those with the -1562 C variant. Also, plasma levels of MMP-9 were much 
higher in -1562 T carriers, than in patients with -1562 C allele (Medley et al., 2004). 
Furthermore, Jones and coauthors have also reported a higher frequency of the -1562 T 
variant in a group of patients with aortic aneurysm (n=414), in comparison to individuals 
with atherosclerotic peripheral vascular disease (n=172, adjusted odds ratio 2.94), or healthy 
control subjects (n=203, adjusted odds ratio 2.41) (Jones et al., 2003). 
Interestingly, subsequent studies, independently conducted by Ogata and Eriksson on large 
groups of aortic aneurysm-suffering individuals (n=387 and n=455, respectively) have failed 
to confirm this association (Ogata et al., 2005; Eriksson et al., 2005). In a large study by 
Smallwood and coauthors, carried out on 678 patients with aortic aneurysms and 659 
healthy controls, no statistically significant association between occurrence of the -1562 T 
allele and development of aortic aneurysm was found (Sandford et al., 2007; Smallwood et 
al., 2008; Saratzis et al., 2011). 
It is noteworthy, that although recent studies have negated the direct involvement of -1562 
C/T polymorphism in pathogenesis of aortic aneurysm, the potential importance of other 
functional polymorphisms in the MMP-9 gene cannot be excluded. Presumably, two 
additional functional SNPs – the first located in the exon encoding for catalytic domain 
(Q279R), and the next relating to the sequence encoding for hemopexin domain (P574R), 
could be considered as attractive candidates for further studies. 
3.2.4 Furin-activated MMPs 
The members of this group are characterized by the presence of an unique RXKR or RRKR 
sequence, inserted between the prodomain and the catalytic domain. This site is recognized 
and cleaved by pro-protein convertases or serine proteinases – furins, thus resulting in an 
activation of enzyme. The furin-activated MMPs are further divided into small subgroups: 
secreted MMPs, membrane-type I and type II MMPs and GPI-anchored MMPs (Fu et al., 
2008; Fanjul-Fernandez et al., 2010). 
The furin-activated secreted MMPs include MMP-11, MMP-21 and MMP-28. In contrast to 
other secreted MMPs, members of this subgroup undergo intracellular processing by furin, 
or furin-like proteases and therefore they are secreted already in active form (Fanjul-
Fernandez et al., 2010). 
3.2.4.1 Membrane type MMPs 
All the membrane type MMPs (MT-MMPs) contain a hydrophobic component that enables 
their insertion in the cell membrane. They control the close neighborhood of both, normal 
and pathological cells, thus being involved in promoting of cell migration, invasion, 
experimental metastasis and angiogenesis (Hernandez-Barrantes et al., 2002). 
Type I transmembrane MMPs include: MT1-, MT2-, MT3-, and MT5-MMP (MMP-14, -15, -
16, and -24, respectively). They are characterized by a long hydrophobic transmembrane 
sequence followed by a short cytoplasmic tail, which could participate in several signaling 
pathways. The main representative of this subgroup, MT1-MMP (MMP-14) may be 
expressed on the cell surface of various cells, however, activated macrophages and VSMC 
are considered as its most important producers. It may cleave native type I collagen into  
¾ – ¼ fragments in a collagenase-specific fashion. Apart from collagen I, MT1-MMP is able 
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to process various components of extracellular matrix, including collagens type II and III, 
gelatin, fibronectin, as well, as non-ECM molecules, e.g. hyaluronan receptor (CD44), 
myelin-inhibitory protein and ǂ-2 macroglobulin (Fanjul-Fernandez et al., 2010). 
Furthermore, as previously mentioned, MT1-MMP plays a key role in the proteolytic 
activation of pro-MMP-2 (see chapter 3.4). 
 
Group Subgroup MMP 
Common 
name 
Substrates 
Extracellular matrix (ECM) Non-ECM 
Gelatinases 
MMP-2 Gelatinase A
Collagens (I, IV, V, VII, X, XI 
and XIV), gelatin, elastin, 
fibronectin, laminin-1, laminin-
5, galectin-3, aggrecan, decorin, 
hyaluronidase-treated versican, 
proteoglycan link protein, 
osteonectin 
IL-1b, ǂ1-PI, 
prolysyl oxidase 
fusion protein, 
MMP-1, MMP-9, 
MMP-13 
MMP-9 Gelatinase B
Collagens (IV, V, VII, X and 
XIV), gelatin, elastin, galectin-3, 
aggrecan, fibronectin, 
hyaluronidase-treated versican, 
proteoglycan link protein, 
entactin, osteonectin 
ǂ1-PI, IL-1ǃ, 
plasminogen 
Furin-
activated 
MMPs 
Secreted 
MMP-11 Stromelysin-3 
Casein, laminin, fibronectin, 
gelatin, collagen IV and 
carboxymethylated transferrin
ǂ1-PI, casein, 
IGFBP-1 
MMP-21 XMMP ND 
MMP-28 Epilysin ND 
Type I 
transmembrane
MMP-14 MT1-MMP 
Collagens (I, II and III), casein, 
elastin, fibronectin, gelatin, 
laminin, vitronectin, large 
tenascin-C, entactin, 
proteoglycans 
ǂ1-PI, MMP-2,-
13 
MMP-15 MT2-MMP 
Large tenascin-C, fibronectin, 
laminin, entactin, aggrecan, 
perlecan 
MMP-2 
MMP-16 MT3-MMP 
Collagen-III, gelatin, casein, 
fibronectin 
MMP-2 
MMP-24 MT5-MMP ND 
GPI-anchored 
MMP-17 MT4-MMP ND 
MMP-25 MT6-MMP ND 
Type II 
transmenbrane
MMP-
23A 
- ND 
MMP-
23B 
- ND 
ND – not determined 
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Recently, it was found, that mRNA and protein levels of MT-MMP-1 were significantly 
higher among patients with an aortic aneurysm, than in healthy controls or atherosclerosis-
suffering subjects. Therefore, it is suggested, that MT-MMP-1 may also be important in 
pathogenesis of aortic aneurysm, especially due to its multidirectional action. Besides direct 
destruction of extracellular matrix components, MT1-MMP activates MMP-2 and facilitates 
migration of macrophages, thus promoting inflammatory infiltration of the aortic wall 
(Kadoglou & Liapis, 2004). 
Type II transmembrane MMPs are represented by enzymes: MMP-23A and MMP-23B, 
which, despite being encoded by two different genes, actually have an identical amino acid 
sequence. Their structure is significantly distinct from other MMPs, since they lack the 
signal peptide, the cysteine-switch motif and the hemopexin domain. Moreover, opposite to 
type I MT-MMPs, they have a transmembrane domain located in their N-terminal tail, 
whereas C-terminus contains a cysteine array and immunoglobulin-like domains (Fanjul-
Fernandez et al., 2010). 
The last subgroup of MT-MMPs includes MT4-MMP and MT6-MMP (MMP-17 and -25, 
respectively). Both of them have the glycosylphosphatidylinositol (GPI) anchor instead of a 
transmembrane domain on their C-terminus, that enables binding of the MMP molecule to 
the cell membrane. To date, little is known about the presumable role of other MT-MMPs in 
pathogenesis of aortic aneurysm, with the exception of MT1-MMP, therefore, this subject 
still requires further studies. 
3.3 Regulation of expression 
The critical role of MMPs in physiology, as well as their involvement in various pathological 
conditions decipher the tight control of production and activation of these enzymes. Among 
all MMPs, only MMP-2 and MMP-9 were found to be expressed constitutively, whereas the 
expression of the remaining members of the MMP family has to be induced, e.g. in response 
to a tissue remodeling, or inflammatory reaction. Numerous factors, including pro-
inflammatory cytokines (IL-1ǃ, IL-6, TNF, etc.), growth factors (platelet-derived growth 
factor – PDGF; epidermal growth factor – EGF; TGF-ǃ; etc.) and corticosteroids are involved 
in the control of MMPs gene expression Kadoglou & Liapis, 2004; Diehm et al., 2007). The 
common feature of the majority of inducible genes, including these encoding for MMPs, is 
the presence of the binding sites for transcription factors AP-1 and/or NF-κB in their 
promoter region. AP-1 transcription factors are heterodimer complexes, composed of two 
proto-oncogene family proteins – Jun and Fos. Together with NF-κB, a p50/p65 
heterodimer, which controls the expression of numerous immune response- and 
inflammation-engaged molecules, AP-1 complexes interconnect a number of growth factor- 
and cytokine-mediated pathways. Another group of transcription factors involved in 
regulation of MMPs expression are members of Ets family. They recognize and bind to the 
conserved polyomavirus enhancer activator protein-3 (Pea3) binding site, which is found in 
MMP promoters. Since the Pea3 binding site is located contiguously to at least one AP-1 
element, the interaction between both transcription factors will presumably modulate 
promoter response to various stimuli. Most recently, it was suggested that, in addition to the 
formerly discussed, the modification of chromatin structure through its acetylation-
deacetylation could be another mechanism, involved in the regulation of MMP genes 
expression. Interestingly, it has been found that inhibition of histone deacetylase (HDAC) 
results in enhanced MMP-3, but decreased MMP-1 and MMP-9 expression in response to 
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stimulation with IL-1ǃ or TNF (Clark et al., 2007; Clark et al., 2008). Therefore, this aspect of 
MMPs expression control remains unclear and requires further studies. The next issue to be 
clarified is the role of mechanotransduction and the involvement of putative 
mechanoreceptors or mechano-responsive elements in MMPs expression control. This 
pathway seems to be of great importance especially in tissues permanently exposed to 
dynamic stress, like joint cartilage chondrocytes or VSMC in blood vessels (Blain, 2007). 
Finally, it is noteworthy, that besides transcriptional level, MMPs expression in response to 
various stimuli, including cytokines and growth factors, may also be controlled by the 
modulation of specific mRNA stability (Chakraborti et al., 2003). 
Most recently, it has been found that MMP-2 activity may also be modulated by protein 
kinase C–mediated phosphorylation at the post-translational level (Sariahmetoglu et al., 
2007). This modification may involve at least 5 amino acid residues from active site of 
catalytic domain and may result in modulation of its activity. Possibly, 3′-5′ cyclic adenosine 
monophosphate (cAMP) pathway may be involved in this step, too. 
3.4 Activation of MMPs 
As mentioned previously, all MMPs are produced and secreted in an inactive zymogen 
form. This status is maintained due to the presence of the “cysteine-switch”, the particular 
interaction between the thiol group of the prodomain cysteine and the zinc ion from the 
catalytic domain. The disruption of this interaction is essential for enzyme activation and 
may occur in two different manners (Fig. 2). 
The first mode is an alteration of the cysteine thiol group by some physiological factors, 
including disulfides, oxidants and electrophiles, as well as non-physiological compounds, 
among them denaturing surfactants with sodium dodecyl sulphate (SDS), alkylating 
agents, organomercurials with 4-aminophenylmercuric acetate (APMA), and heavy metal 
ions. This alteration results in some allosteric changes in MMP structure, followed by an 
exposure of the catalytic site of the enzyme. It may lead to the auto-cleavage and removal 
of prodomain, and thus is associated with reduction of enzyme molecular size. On the 
other hand, the prodomain may stay attached to the active enzyme and thus the 
molecular weight of activated MMP remains unchanged (Fu et al., 2008; Hadler-Olsen et 
al., 2011) (Fig. 2A). 
The second mechanism of MMPs activation is direct cleavage of their prodomain by another 
proteolytic enzyme. It has been shown that proteolytic activation of MMPs may be 
conducted by other MMPs, as well as a broad spectrum of extracellular serine-, cysteine- or 
aspartate-proteinases. Moreover, this mechanism is also utilized during an intracellular 
activation of MMPs by furin, the subtilisin-like serine proteinase from the trans-Golgi 
network (Fig. 2A). 
An interesting combination of both, allosteric and proteolytic mode of action, represents 
activation of MMP-2 by the membrane type 1-MMP (MT1-MMP, or MMP-14) in the 
presence of the endogenous MMP inhibitor – the tissue inhibitor of MMPs (TIMP)-2. The 
TIMP-2 molecule serves as a link between MMP-2 and MMP-14, where the N-terminal 
part of TIMP-2 inactivates MMP-14 and its C-terminal part binds to the hemopexin 
domain of pro-MMP-2 (Fig. 2B). The prodomain of immobilized MMP-2 is then cleaved 
by another recruited MMP-14 molecule, thus resulting in proteolytic activation of MMP-2. 
Remarkably, other membrane type MMPs: MT2-MMP and MT3-MMP are able to activate 
pro-MMP-2 without involvement of TIMP (Hadler-Olsen et al., 2011, Klein & Bischoff, 
2010). 
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Fig. 2. The MMP activation pathways (a detailed description in text) 
3.5 Inhibition of MMPs 
When firmly supervised, matrix metalloproteinases control various physiological reactions 
very precisely. However, if this supervision appears incompetent, MMPs reveal their “dark 
side of the Force” and become highly dangerous molecules, which are engaged in many 
pathologies, including the development of an aortic aneurysm. Therefore, mechanisms 
responsible for this regulation and factors participating in these mechanisms are potentially 
useful in some therapeutic approaches.  
Standard mechanisms of MMPs silencing include interaction with the specific tissue 
inhibitors of metalloproteinases and other endogenous inhibitors, such as ǂ2-macroglobulin, 
reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and tissue-factor-
pathway-inhibitor 2 (TFPI2) (Maskos & Bode, 2003). 
Surprisingly, although reactive oxygen species are known to activate autolytic cleavage of 
MMPs due to disruption of their “cysteine switch”, it has been suggested that oxidants may 
also inactivate MMPs by modification of some amino acids critical for their catalytic activity 
(Fu et al., 2008). 
3.5.1 TIMPs 
Tissue inhibitors of metalloproteinases are secreted by different types of cells, including 
macrophages, VSMC and platelets. The basically defined function of TIMPs is a suppression 
of the MMPs activity by biding to their catalytic domain and blocking enzymatic activity. 
Based on in vitro studies, TIMPs are recognized as highly efficient MMPs inhibitors (with Ki 
at the level of 10-11 M for TIMP-1/MMP-1 interaction). The affinity of various TIMPs to 
specific MMPs differs among them, e.g. TIMP-1 preferably binds to MT-MMPs, whereas 
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other TIMPs are generally less selective. However, a direct interaction between TIMPs and 
active MMPs may be difficult to observe in vivo, mainly due to a presence of ǂ2-
macroglobulin, a common MMP-neutralizing agent (Fu et al., 2008). On the other hand, as 
clearly shown for TIMP-2, as well as for other TIMPs, their binding to the hemopexin 
domain of pro-MMP-2 is actually necessary for the activation of this enzyme by MT1-MMP 
(Hadler-Olsen et al., 2011). 
It is plausible, that functional polymorphisms in genes encoding for TIMPs could influence 
the activity of MMPs in the aneurysm wall. Thus, several SNPs supposed to affect the level 
of TIMP transcription, were assessed in patients with aortic aneurysms. It is noteworthy, 
that the genotyping results were analyzed for male and female patients separately due to 
the fact, that TIMP-1 gene is located on the X chromosome. To date, the association with 
aortic aneurysm has been suggested for two polymorphisms in gene for TIMP-1 (434 C/T 
and rs2070584 T/C) (Ogata et al., 2005) and two in TIMP-2 (a promoter SNP -479 C/T, and 
573 G/A, but in male patients group only) (Wang et al., 1999; Hinterseher et al., 2007). 
Nevertheless, since the mentioned analyses concerned relatively small groups, this issue still 
requires additional investigation (Sandford et al., 2007; Saratzis et al., 2011). 
3.5.2 Pharmacological modulation of MMPs 
Since the modulation of MMPs activity by endogenous inhibitors in pathology seems to be 
inefficient, several strategies with exogenous MMP modulators have been developed. It is 
noteworthy, that some of these modulators are already used in clinical practice, although 
the primary indication for their application did not concern inhibition of MMPs. 
An interesting approach may be the use of MMP-specific antibody-based inhibitors. The 
experimental model with neutralizing antibodies directed against MMP-2 has shown their 
protective influence on a heart exposed to ischemia/reperfusion injury (Cheung et al., 2000). 
However, the verification, whether this procedure would be useful in management of aortic 
aneurysms, needs further studies. Apart from endogenous inhibitors, various 
pharmacological agents may reveal inhibitory activity against MMPs. The small 
hydroxamate-based zinc-chelating synthetic agents, such as batimastat, marimastat or 
ilomastat (galardin), were first used in oncology, to suppress MMPs-dependent metastasis 
and tumor invasion. However, due to non-selective, generalized inhibition of MMPs activity 
with numerous adverse events, accompanied by relatively poor effectiveness, their clinical 
career was ended very soon (Baxter, 2004). 
3.5.2.1 Tetracyclines 
Tetracyclines are natural antibiotics derived from Streptomyces. They are known for many 
non-antibiotic properties, including inhibition of proteolysis, or anti-apoptotic and anti-
inflammatory activity. The most intensively tested representative of tetracyclines – 
doxycycline, has been shown to prevent formation of aortic aneurysm in several animal 
models. Also, the results of three small clinical trials in humans have shown that 
doxycycline in a well tolerated dose 150-200 mg/day significantly reduced aneurysm 
expansion rate. It has been suggested, that doxycycline inhibits MMPs directly, by binding 
to their catalytic site. Furthermore, it may reduce the MMP expression attenuating the 
inflammatory cascade. However, the results of the studies on putative effects of tetracyclines 
on MMP-9 are not fully consistent. The first published study by Cruci and coauthors has 
shown that doxycycline treatment in a dose 200 mg/day resulted in a 2.5-fold reduction of 
MMP-9 protein levels and 82% reduction of MMP-9 mRNA expression (Cruci et al., 1998). 
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Surprisingly, in a subsequent placebo-controlled study Ding and colleagues did not observe 
any effect of 1 month 100 mg/day doxycycline therapy on MMP-9 mRNA, or protein 
expression (Ding et al., 2005). Finally, Lindeman and coauthors have shown that 2-weeks 
doxycycline treatment decreased MMP-9 protein levels (p<0.0026), but did not affect mRNA 
expression level (p=0.206). The authors have concluded, that the beneficial effect of 
doxycycline on aneurysm progression might be due to the reduction of aneurysm wall 
infiltration by neutrophils and T CD8-positive lymphocytes rather, than the decrease of 
MMP-9 gene expression (Lindeman et al., 2009). 
3.5.2.2 Macrolides 
The beneficial influence of tetracyclines on aneurysm expansion rate may be 
multidirectional, including their antimicrobial activity against Chlamydia pneumoniae, and 
thus, indirect MMPs modulation (also discussed in chapter 2.2). This concept led to the 
introduction of macrolides, other antibiotics with potent Chlamydia-killing activity, to the 
arsenal of anti-aneurysm agents. In a randomized trial by Vammen and coauthors, the aortic 
aneurysm expansion rate in patients treated with roxithromycin was 1.56 mm/year, in 
comparison to 2.75 mm/year in the placebo-receiving control group. Interestingly, no 
significant correlation between C. pneumoniae titers and roxithromycin ability to suppress 
the aneurysm expansion was observed (Vammen et al., 2001) . 
The mechanism of anti-aneurysm protective action of macrolides remains unclear. 
Recently, another macrolide derivative, rapamycin, was tested in animal aortic aneurysm 
model. Due to its strong anti-inflammatory and immunosuppressive properties, 
rapamycin is commonly used to prevent transplanted organ rejection. It has been found, 
that rapamycin administration in experimentally induced aortic aneurysms in rat 
significantly inhibits activation of NF-κB and, subsequently, MMP-9 expression thus 
resulting in 40% decrease of aneurysm expansion rate, as compared to control animals 
(Lawrence et al., 2004). 
3.5.2.3 Statins 
The inhibitors of hydroxymetylglutaryl-coenzyme A reductase, better known as statins, are 
widely used in a treatment of patients with cardiovascular diseases. Apart from their main 
activity, which decreases atherogenic lipoproteins, statins reveal various pleiotropic effects, 
including an augmentation of pro-apoptotic properties of some anticancer drugs, or an 
inhibition of inflammatory cell activity. Possibly, these anti-inflammatory properties of 
statins result from suppression of NF-κB, that is also involved in regulation of MMPs 
expression. Indeed, in vitro studies have demonstrated, that simvastatin and cerivastatin 
may decrease the production of MMPs, especially MMP-9, in VSMC, macrophages and 
neutrophils. A subsequent small clinical study by Nagashima, and a randomized 
prospective trial by Evans group independently showed, that statins were potent inhibitors 
of inflammatory cells in vivo, and they effectively suppressed the MMP-9 production in the 
aortic aneurysm wall (Nagashima et al., 2002; Evans et al., 2007). Also, Wilson and his 
colleagues observed, that simvastatin, pravastatin and atorvastatin decreased local 
concentrations of MMP-3 and MMP-9 in the anterior wall of aortic aneurysms in patients 
undergoing open heart surgery. Furthermore, as shown by Schouten and coauthors, statin 
use resulted in lower aneurysm expansion rate with 2.0 mm/year in statin-treated versus 3.6 
mm/year in the placebo control group (Schouten et al., 2006). Interestingly, in contrast to 
reports mentioned previously, Hurks and coauthors did not observe any statistically 
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significant differences in MMP-9 level between patients treated with statins and a control 
group. Moreover, they have found, that a level of active MMP-9 in patients treated with 
pravastatin was higher, than in control subjects (Hurks et al., 2010). This may suggest, that a 
pleiotropic actions profile of these drugs may differ among the various statins. 
Unfortunately, the issue concerning statins influence on aortic aneurysm progression seems 
unlikely to be resolved in the near future, because of two reasons at least. Firstly, the 
prevalence of statin use in aortic aneurysm-suffering patients is very high, mainly due to 
other concomitant cardiovascular diseases. Therefore, it may be difficult to assemble a 
control group for a large randomized study. Secondly, according to current 
recommendations, statins should be used as perioperative protection during open surgical, 
as well as endovascular aneurysm repair (Diehm et al. 2007). Thus, such a study, 
additionally to being difficult to design, appears to be ethically controversial. 
3.5.2.4 Low molecular weight heparin 
As was discussed previously (chapter 2.1), the aortic aneurysm is usually accompanied by 
an intraluminal thrombus, that is always associated with more or less clinically overt 
coagulation abnormalities. It has been shown, that these coagulopathies may be successfully 
treated with small doses of low molecular weight heparin (LMWH) (Jelenska et al., 2004). 
Moreover, our subsequent studies revealed, that in addition to the attenuation of 
coagulation abnormalities, a LMWH treatment resulted in statistically significant decrease 
of circulating MMP-9 plasma activity. Interestingly, the in vitro studies did not show any 
direct influence of LMWH on MMP-9 production by activated leucocytes, or enzyme 
activity, either. Therefore, the most plausible explanation seems to be an indirect mechanism 
of LMWH action. According to our concept, the stabilized thrombus does not capture any 
new leukocytes. In such circumstances the number of MMP-9-producing cells, which are 
already entrapped in fibrin clot, decreases slowly. Finally, theses conditions lead to the 
decrease of MMP-9 amounts, released from intraluminal thrombus to the circulating blood. 
However, the verification of this hypothesis, as well as further clinical studies, concerning 
LMWH influence on aneurysm progression, are necessary. 
3.5.2.5 JNK inhibitor 
Based on results of studies focused on molecular aspects of aortic aneurysm 
pathophysiology, the c-Jun N-terminal kinase (JNK) has been selected as a new target for 
therapy. Using pharmacological JNK inhibitor Yoshimura and coauthors prevented the 
development, or induced the regression of already formed aneurysm in calcium-, or 
angiotensin II-induced aortic aneurysm mouse models. This effect was associated with 
decreased MMP-9 activity, but also with restoration of aortic tissue architecture, mainly due 
to the upregulation of various extracellular matrix proteins synthesis. Obviously, the results 
of further studies are expected highly impatiently (Yoshimura et al., 2005; Miyake & 
Morishita, 2009). 
3.5.2.6 Renin-angiotensin system modulators 
Recently, it has been suggested, that the renin-angiotensin system and its main effector 
molecule – angiotensin II, may also be involved in the initiation of inflammatory reaction in 
the aortic wall and, thus, it significantly contributes to the development of aneurysm. 
Therefore, antagonists of the angiotensin II receptor were tested for their presumable 
protective effect on aneurysm progression. Indeed, it was shown, that losartan and 
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valsartan, two representatives of the group, were effective in preventing aneurysm 
formation. Interestingly, although they do not appear to influence MMPs activity directly, 
their beneficial influence was associated with decrease of MMPs expression in aneurismal 
tissue, possibly due to the suppression of NF-κB-controlled inflammatory reaction (Fujiwara 
et al., 2008; Miyake & Morishita, 2009). However, since the career of angiotensin II receptor 
antagonists in a management of cardiovascular diseases is rather short, their value in aortic 
aneurysm treatment still remains to be verified. 
The next group of pharmaceuticals, addressed to interfere with the renin-angiotensin system 
are angiotensin converting enzyme (ACE) inhibitors. In contrast to the previously described 
angiotensin II receptor antagonists, they bind to the active site of MMPs and directly block 
their enzymatic activity in a dose dependent manner. Using animal models, it has been shown, 
that ACE inhibitors, including captopril, enalapril, lisinopril and perindopril, reduced the 
aortic wall degeneration and aneurysm progression. Surprisingly, data provided by several 
clinical trials are highly inconsistent. Reports by Lederle and Taylor, or Hackam group 
suggested independently, that patients with aortic aneurysms, which received ACE inhibitors, 
displayed lower aneurysm expansion rate and were better protected from aneurysm rupture, 
as compared to individuals treated without convertase inhibitors (Hackam et al., 2006; Lederle 
& Taylor, 2006). On the other hand, Schouten and colleagues did not find any correlation 
between aneurysm dilatation rate and ACE inhibitors (Schouten et al., 2006; Baxter et al., 2008; 
Miyake & Morishita, 2009). Moreover, the abdominal aortic aneurysm screening program in 
UK revealed an increasing aneurysm growth rate, that was apparently associated with ACE 
inhibitors intake (Sweeting et al., 2010). Therefore, this approach urgently needs further 
elucidation in multicenter prospective randomized trials, although, due to the common use of 
ACE inhibitors in cardiovascular diseases, the study design will possibly meet similar 
obstacles, as in statins case. 
3.5.2.7 Decoy oligodeoxynucleotides 
Recently, the novel strategy based on targeting transcription factors, which are known to be 
involved in regulation of inflammatory reaction and MMPs expression, appears to be highly 
promising approach in the management of aortic aneurysm. A principle of this strategy is 
the use of synthetic oligodeoxynucleotides (ODNs), referred as “decoy” ODNs, which 
specifically recognize and bind to respective transcription factors and thus competitively 
block their binding to promoter of gene of interest. 
This decoy strategy was used to inhibit two transcription factors – NF-κB and ets-1, which 
are suggested to control gene expression of several MMPs, including MMP-1, -2, -3 and -9. 
Using elastase-induced aneurysm rat and rabbit models, and chimeric anti-NF-κB/ets-1 
decoy ODNs, Miyake and colleagues have analyzed the effects of the simultaneous 
suppression of both, NF-κB and ets-1. They found, that this approach resulted in marked 
decrease of aortic aneurysm progression, that was accompanied by significant decrease of 
MMP-1 and MMP-9 expression in the aneurysm wall. Moreover, in the rabbit model the 
application of the mentioned decoy system onto already formed aneurysms led to their 
significant regression, which in addition to MMPs inhibition, was possibly due to induction 
of collagen and elastin synthesis, that is negatively controlled by ets-1. Hopefully, this 
strategy will be effective also in human, since the anti-NF-κB/ets-1 ODNs decreased MMPs 
expression in ex vivo experiments with cultured human aortic tissue (Miyake & Morishita, 
2009). It is noteworthy, that the decoy ODNs-based therapy has some limitations, too. The 
main problem is the rapid degradation and relatively short half-life of therapeutic ODNs, 
www.intechopen.com
 Etiology, Pathogenesis and Pathophysiology of Aortic Aneurysms and Aneurysm Rupture 
 
44
that require their local application. This in turn raises the problem with an effective delivery 
system. In experiments by Miyake and coauthors the cellulose-based ODNs delivery system 
was applied intraoperatively on the outer surface of dilated aorta. In clinical practice this 
could be done using low-invasive procedures, such as laparoscopy, or more likely by 
endovascular access. However, this issue remains to be resolved.  
3.6 Methods of MMP detection and analysis 
The increasing evidence concerning the involvement of MMPs in various pathologies, 
including aortic aneurysm, results in the necessity to develop methods of analysis that 
would be sufficiently sensitive and specific enough to detect minute amounts of MMPs. 
3.6.1 ELISA 
The above mentioned main requirements are met by an enzyme-linked immunosorbent 
assay (ELISA). Despite its high sensitivity (picograms per ml) and availability for all known 
MMPs, the ELISA method provides data reflecting only the specific protein amount, 
without any information about its enzymatic activity. This obstacle is partially resolved by a 
new generation of ELISA kits, that can discriminate between full length pro-enzyme and 
proteolytically activated MMP (Fig. 3A). Obviously, similar data could be obtained using 
the western-blot method with respective anti-MMP antibodies. Nevertheless, the previously 
mentioned non-proteolytic activation of full-length molecules may result in false negative, 
or at least, underestimated results of MMP measurement. Thus, the studies focusing on 
MMPs require another method that would enable convenient analysis of their enzymatic 
activity.  
3.6.2 Substrate-specific zymography 
Currently, the standard method used for the analysis of MMPs activity is a substrate-specific 
zymography with sodium dodecyl sulphate (SDS)-polyacrylamide gel electrophoresis 
(PAGE). The method is based on a molecular size-dependent electrophoretic separation of 
tested samples in a polyacrylamide gel, containing substrate specific for MMP being 
analyzed, e.g. gelatin for MMP-2 and MMP-9, casein for MMP-1, -3, -7, -10, -12 and -13 or 
collagen for MMP-1 and -13 (Kupai et al., 2010). Then, the gel is incubated in zinc- and 
calcium-rich reaction buffer to re-activate enzyme particles separated in the gel. The high 
local concentration of enzyme molecules results in a substrate digestion, that is restricted to 
the area close to the position of respective MMP in the gel. The visualization of enzymatic 
activity of assayed samples occurs after incubation of the whole gel with the staining 
solution, e.g. Coomassie blue. The presence of an unstained area in a gel corresponds to a 
substrate cleavage, due to enzymatic activity of respective MMP, whereas the size of this 
area directly correlates with amount and/or activity of the enzyme. Thus, the standard SDS-
PAGE zymography allows a semi-quantitative comparison of respective MMP amount, or 
more precisely – activity between various samples. When used with known amounts of 
recombinant MMP, as a reference, the method permits the quantitative assessment of 
respective MMP. Furthermore, due to the gel electrophoresis of analyzed samples, this 
method enables the molecular size-based identification and individual measurement of 
both, full length pro-MMP and its short processed form, too (Fig. 3D, also Fig.2). It has been 
proven that sensitivity of standard SDS-PAGE zymography is sufficient to detect similar 
amounts of active MMP, as those using ELISA method (Table 1). 
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Substrate Enzyme Detection limit 
gelatin MMP-2 10 pg 
casein MMP-7 1 ng 
collagen MMP-1 0.1 pg 
Table 1. Examples of SDS-PAGE zymography detection limits (Kupai et al., 2010) 
It is noteworthy, that the standard SDS-PAGE zymography is not free of some problems, 
either. The important issue is the unspecific, SDS-mediated activation of pro-MMP, that may 
occur during electrophoresis. Obviously, this event affects the results, and is usually 
associated with an overestimation of MMP activity. Additional difficulty with the use of this 
method is the long, time-consuming procedure. Therefore, although the SDS-PAGE 
zymography is sensitive enough and relatively inexpensive, in some circumstances the 
better choice for a fast MMP assessment could be the fluorescent zymography. 
3.6.3 Fluorescent zymography 
The fluorescent zymography is based on a technology known as the fluorescence resonance 
energy transfer (FRET). Briefly, the tested sample is incubated in small volume (10-20 μl) of 
reaction mixture containing the substrate, that is labeled with fluorochrome and quencher 
tags. When a substrate remains intact, the energy emitted by fluorochrome is entirely absorbed 
by the quencher, therefore no fluorescence is detected. The substrate degradation abolishes the 
suppressive effect of the quencher on fluorochrome, thus resulting in increase of fluorescence 
in the reaction mixture. The intensity of fluorescence corresponds to the amount of digested 
substrate, that, in turn, reflects the amount of active enzyme in a sample (Fig. 3B). 
 
 
Fig. 3. Schematic representation of main methods of MMPs detection (description in text). 
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Oppositely to standard SDS-PAGE zymography, this method is very fast and enables the 
measurement of proteolytic activity in analyzed samples within several minutes. In contrast 
to the previously mentioned ELISA and SDS-PAGE zymography, the fluorescent 
zymography allows an assessment of the direct influence of various factors on MMP 
activity. However, the outcome of the analysis is highly sensitive to sample preparation and 
the reaction conditions. The samples should be prepared without addition of EDTA or other 
metal-ion chelators, and without addition of protease inhibitors. This step may be of great 
importance for final results of analysis, especially since the extraction procedures 
themselves may induce MMPs activation or lead to release of natural MMP inhibitors. After 
tissue disruption during sample preparation, these inhibitors, although initially localized in 
different compartments, can interact with active enzymes, and thus, may affect the results of 
assay. Another important issue may be the concentration of non-ionic detergents in the 
reaction mixture, which may “neutralize” small molecules that potentially could interfere 
with MMP activity (Kupai et al., 2010). 
The most significant disadvantage of the fluorescent zymography is, that it does not 
determine MMP, that directly contributes to the observed substrate degradation. This 
obstacle may be omitted by the use of respective, MMP-specific, monoclonal antibodies, 
which block the proteolytic activity of the selected enzyme. With a panel of blocking 
antibodies, this modification allows the quantitative assessment of each constituent of 
MMP-mediated proteolytic activity in the analyzed sample. 
Another solution to this problem may be the method that combines the idea of both, ELISA 
and fluorescent zymography. Briefly, the plate is coated with specific anti-MMP antibodies, 
which capture molecules of the respective enzyme from the sample being assessed. Then, non-
captured, unspecific proteins are washed out and the fluorochrome/quencher-labeled 
substrate is added to the plate followed by incubation. Finally, since the intensity of MMP-
mediated fluorescence corresponds to the activity of specific MMP, it may be measured using 
the fluorescence plate reader. This solid-phase, or immunocapture fluorescent zymography 
represents the key advantages of both, ELISA and “normal” fluorescent zymography (Fig. 3C). 
It enables a measurement of enzymatic activity of individual MMPs, is specific, sensitive, rapid 
and lacks the previously mentioned main deficiencies of both methods. 
3.6.4 In situ zymography 
In studies concerning distribution of MMPs in affected tissues, the use of in situ 
zymography may be very advantageous. This test allows the detection of MMPs activity in 
histological specimens, directly on the place of their production or activation. Similarly to 
previously mentioned fluorescent zymography, this method also exploits FRET technology. 
The fluorochrome/quencher-labeled substrate is applied on the surface of a specimen, and 
is incubated. Then, the specimen can be assessed with a fluorescent microscope, or using a 
confocal laser scanning microscope. 
The main disadvantage of this method is that it does not allow precise measurement of the 
amount of active MMP. Moreover, similarly to “normal” fluorescent zymography, it is 
necessary to use neutralizing antibodies, to determine MMPs that contribute to substrate 
cleavage. 
3.6.5 Reverse zymography - detection of MMP inhibition 
The studies concerning the role of MMP in pathogenesis of aortic aneurysm include also a 
method that enables assessment of the natural tissue inhibitors of MMP (TIMPs). This 
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method, known as reverse zymography, utilizes polyacrylamide gel with specific 
substrate, that is additionally supplemented with respective MMP. After electrophoresis 
of tested samples the gel is subjected to the same processing as in routine zymography. 
Then, the MMP, which is equally distributed in the whole gel, cleaves the substrate with 
the exception of those places, where TIMPs inhibit its proteolytic activity. Those places are 
visible as Coomassie blue-stained bands, whereas the other parts of the gel remain 
unstained. 
In addition to reverse zymography, the expected interaction between MMPs and their tissue 
inhibitors can also be analyzed using a modified western blotting (SDS-PAGE and 
immunoblotting) method. The formation of higher molecular weight complex by interacting 
molecules results in its slower migration during polyacrylamide gel electrophoresis, and 
thus reveals a band shift of specific MMP or its inhibitor, depending on the antibody used 
for detection. 
3.6.6 Possible applications 
Currently, the methods of MMPs analysis in aortic aneurysm clinics described above  
are predominantly used for research purpose. However, due to an increasing interest in 
the monitoring of MMPs level and/or activity in aneurysm-suffering patients, it is 
plausible that some of these methods will become the standard diagnostic tools in the 
near future. 
The first postulated indication for clinical use could be the screening of plasma MMPs 
activity in patients with newly recognized aortic aneurysm. Although there is no consent, 
whether low plasma levels of MMPs may be considered as a low risk indicator of aneurysm 
progression and/or rupture, it is nevertheless widely accepted that the higher 
concentration, or more precisely, their higher activity should at least encourage more 
frequent monitoring of aneurysm diameter. The second, important clinical application for 
MMP assessment seems to be the periodic monitoring of MMPs activity in patients with 
small aneurysms and subjected to pharmacological treatment. Obviously, the method 
selected for monitoring should depend on the mechanism of action of controlled MMP 
modulator. Thus, the monitoring of pharmacological treatment of aortic aneurysm using 
compounds displaying indirect influence on MMP amount and/or activity, including 
statins, heparins or ODNs, may engage a broad spectrum of methods mentioned above. 
However, in regimens using potent direct MMP inhibitors, e.g. tetracycline-derivatives, or 
angiotensin converting enzyme-inhibitors, the fluorescent zymography rather, than other 
methods, including substrate-specific SDS-PAGE zymography, should be used 
preferentially. 
It has been found that open aneurysm repair leads to transient (usually within first 3 moths)  
MMP-9 increase, followed by its later significant reduction. Nevertheless, in some patients 
high levels of MMPs may still persist even a very long time after surgery (Kadoglou & 
Liapis, 2004). An interesting example of this condition may by the case of a 50-year old men 
with an abdominal aortic aneurysm, subjected to successful open aneurysm repair. 
Surprisingly, after 4 years the patient was qualified again for surgical treatment due to the 
significant enlargement of the thoracic aorta, remaining suprarenal part of abdominal aorta 
and common iliac arteries. The plasma level of MMP-2 was similar to those observed in 
other aortic aneurysm-suffering individuals. However, his MMP-9 plasma activity was 
extraordinarily (almost 10-fold) higher, than mean MMP-9 level, observed in other patients 
bearing an aortic aneurysm. 
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In contrast to open repair, patients subjected to endovascular aneurysm exclusion usually 
reveal a gradual decrease of circulating MMP-3 and -9, whereas the persisting high 
concentration and/or activity of circulating MMP-9 actually correlates with some 
postoperative complications. They include graft migration, or presence of endo-leak, where 
both conditions are accompanied by the contact of circulating blood with the thrombus still 
existing in the aneurysm lumen (Kadoglou & Liapis, 2004). Therefore, the temporary 
monitoring of MMP activity may be an important diagnostic procedure also in patients after 
both, open surgical, but also endovascular intervention. 
4. Conclusion 
Despite numerous studies, the role of MMPs in pathogenesis of aortic aneurysm remains 
unclear. Also, the question, whether they are “executors”, or “executioners”, is still 
unanswered. Since MMPs are obviously engaged in all stages of the aneurysm development, 
from the beginning, till the fatal aneurysm rupture, they are very attractive targets in 
approaches, concerning pharmacological treatment of this pathology. However, due to some 
discrepancies between results of experimental, as well as clinical studies conducted so far, 
this issue still requires intensive research. Nevertheless, it is plausible that in the near future 
the majority of patients with aortic aneurysms might simply require regular drug intake, 
without the necessity for surgical intervention, which would be reserved for particular cases 
only. Since it is very similar to the history of management of gastric ulcers, this vision seems 
to be quite realistic in the near future… 
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